Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma

Cancer Discovery

Volumn 6, Issue 1, 2016, Pages 59-70

  Devlin, Jennifer R ^a   Hannan, Katherine M ^a,b   Hein, Nadine ^a,b   Cullinane, Carleen ^a,c   Kusnadi, Eric ^a,c   Ng, Pui Yee ^a   George, Amee J ^a,b,d   Shortt, Jake ^a,c   Bywater, Megan J ^a   Poortinga, Gretchen ^a,c   Sanij, Elaine ^a,c   Kang, Jian ^a   Drygin, Denis ^e   O’Brien, Sean ^f   Johnstone, Ricky W ^a,c   McArthur, Grant A ^a,c   Hannan, Ross D ^a,b,c,d,g   Pearson, Richard B ^a,c,g  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Australian National University   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Pimera   (United States)

^f Senhwa Biosciences   (United States)

^g MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CX 5461; EVEROLIMUS; MYC PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; MYC PROTEIN, HUMAN; NAPHTHYRIDINE DERIVATIVE; RIBOSOME DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; BIOGENESIS; BONE MARROW CELL; CANCER SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN SYNTHESIS; RIBOSOME; RNA TRANSLATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; HUMAN; LYMPHOMA, B-CELL; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOTHIAZOLES; DNA, RIBOSOMAL; DRUG SYNERGISM; EVEROLIMUS; HUMANS; LYMPHOMA, B-CELL; MICE; NAPHTHYRIDINES; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84954064847     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0673     Document Type: Article

References (55)

1. Baker V, Borst M, Dixon D, Hatch K, Shingleton H, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 1990;38:340-2.
2. Dang CV. MYC on the path to cancer. Cell 2012;149:22-35.
3. Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer 2010;1:605-16.
4. Horiuchi D, Kusdra L, Huskey N, Chandriani S, Lenburg M, Gonzalez-Angulo A, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. Journal Exp Med 2012;209:679-96.
5. Koh C, Bieberich C, Dang C, Nelson W, Yegnasubramaian S, De Marzo A. MYC and prostate cancer. Genes Cancer 2010;1:617-28.
6. Zhuang D, Mannava S, Grachtchouk V, Tang W, Patil S, Wawrzyniak J, et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 2008;27:6623-34.
7. Ji H, Wu G, Zhan X, Nolan A, Koh C, De Marzo A, et al. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS One 2011;6:e26057.
8. Dang C. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 2013;3:pii: a014217.
9. Poortinga G, Quinn L, Hannan R. Targeting RNA polymerase I to treat MYC-driven cancer. Oncogene 2015;34:403-12.
10. Poortinga G, Wall M, Sanij E, Siwicki K, Ellul J, Brown D, et al. c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. Nucleic Acids Res 2011;39:3267-81.
11. Poortinga G, Hannan K, Snelling H, Walkley C, Jenkins A, Sharkey K, et al. MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J 2004;23:3325-35.
12. Bywater M, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012;22:51-65.
13. Bywater M, Pearson R, McArthur G, Hannan R. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer 2013;13:299-314.
14. Drygin D, Lin A, Bliesath J, Ho C, O'Brien S, Proffitt C, et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res 2011;71:1418-30.
15. Hannan RD, Drygin D, Pearson RB. Targeting RNA polymerase I transcription and the nucleolus for cancer therapy. Expert Opin Ther Targets 2013;17:873-8.
16. Hein N, Hannan K, George A, Sanij E, Hannan R. The nucleolus: an emerging target for cancer therapy. Trends Mol Med 2013;19:643-54.
17. Quin J, Devlin J, Cameron D, Hannan K, Pearson R, Hannan R. Targeting the nucleolus for cancer intervention. Biochim Biophys Acta 2014;1842:802-16.
18. Pourdehnad M, Truitt M, Siddiqi I, Ducker G, Shokat K, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A 2013;110:11988-93.
19. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, et al. The translation factor eIF-4E promotes tumor formation and co-operates with c-Myc in lymphomagenesis. Nat Med 2004;10:484-6.
20. Chan J, Hannan K, Riddel K, Ng P, Peck A, Lee R, et al. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci Signal 2011;4:ra56.
21. Hannan KM, Sanij E, Rothblum LI, Hannan RD, Pearson RB. Dysregulation of RNA polymerase I transcription during disease. Biochimi Biophys Acta 2013;1829:342-60.
22. Jefferies H, Fumagalli S, Dennis P, Reinhard C, Pearson R, Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 1997;16:3693-704.
23. Sheppard K, Kinross K, Solomon B, Pearson R, Phillips W. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 2012;17:69-95.
24. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
25. Hannan K, Brandenburger Y, Jenkins A, Sharkey K, Cavanaugh A, Rothblum L, et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol 2003;23:8862-77.
26. Jastrzebski K, Hannan K, Tchoubrieva E, Hannan R, Pearson R. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 2007;25:209-26.
27. Devlin J, Hannan K, Ng P, Bywater M, Shortt J, Cullinane C, et al. AKT signalling is required for ribosomal RNA synthesis and progression of Eu-MYC B-cell lymphoma in vivo. FEBS J 2013;280:5307-16.
28. Wall M, Poortinga G, Stanley K, Lindermann R, Bots M, Chan J, et al. The mTORC1 inhibitor everolimus prevents and treats Eu-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov 2013;3:82-95.
29. Shortt J, Martin B, Newbold A, Hannan K, Devlin J, Baker A, et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 2013;121:2964-74.
30. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008;456:971-5.
31. Hsieh A, Truitt M, Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Brit J Cancer 2011;105:329-36.
32. Shah N, Kasap C, Weier C, Balbas M, Nicoll J, Bleickardt E, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008;14:485-93.
33. Flaherty K, Infante J, Daud A, Gonzalez R, Kefford R, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
34. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009;16:369-77.
35. Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011;117:2567-76.
36. Drygin D, O'Brien S, Hannan R, McArthur G, Von Hoff D. Targeting the nucleolus for cancer specific activation of p53. Drug Discov Today 2014;19:259-65.
37. Woods S, Hannan K, Pearson R, Hannan R. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy. Biochim Biophys Acta 2015;1849:821-9.
38. Silvera D, Formenti S, Scheider R. Translational control in cancer. Nat Rev Cancer 2010;10:254-66.
39. Grepsi F, Soratroi C, Krumschnabel G, Sohm B, Ploner C, Geley S, et al. BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent protein synthesis. Cell Death Differ 2010;17:1672-83.
40. Donati G, Bertoni S, Brighenti E, Vici M, Trere D, Volarevic S, et al. The balance between rRNA and ribosomal protein synthesis upand downregulates the tumour suppressor p53 in mammalian cells. Oncogene 2011;30:3274-88.
41. Kao C, Hsu H, Chen H, Cheng T. Rapamycin increases the p53/ MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells. Cancer Lett 2009;286:250-9.
42. Hewett Y, Uprety D, Shah B. Idelalisib-a PI3K44targeting agent for B-cell malignancies. J Oncol Pharm Pract 2015 Feb 23. [Epub ahead of print].
43. Sanford D, Wierda W, Burger J, Keating M, O'Brien S. Three newly approved drugs for chronic lymphocytic leukemia: incorporating Ibrutinib, Idelalisib and Obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk 2015;15:385-91.
44. Shortt J, Johnstone RW. Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol 2012;4.
45. McKeown M, Bradner J. Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med 2014;4:pii: a014266.
46. Zuber J, Shi J, Wang E, Rappaport A, Herrmann H, Sison E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
47. Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
48. Dawson M, Prinjha R, Dittman A, Giotopoulos G, Bantscheff M, Chan W, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478: 529-33.
49. Bouabdallah K, Ribrag V, Terriou L, Soria J, Delarue R. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr Opin Oncol 2013;25:S1-S12.
50. Cheung K, Horsman D, Gascoyne R. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Brit J Haemat 2009;146:257-69.
51. Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ 2006;13:129-40.
52. Ploner C, Rainer J, Niederegger H, Eduardoff M, Villunger A, Geley S, et al. The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia. Leukemia 2008;22:370-7.
53. Pinon J, Labi V, Egle A, Villunger A. Bim and Bmf in tissue homeostasis and malignant disease. Oncogene 2008;27:S41-S52.
54. Markman B, Tao JJ, Scaltriti M. PI3K pathway inhibitors: better not left alone. Curr Pharm Des 2013;19:895-906.
55. Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman K, et al. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Brit J Haemat 2004;127:285-91.